Cagrilintide

What is Cagrilintide?
Cagrilintide is a long-acting amylin analog. Monotherapy phase 2 showed weight loss of 6-10%; combination with semaglutide pushed total weight loss above 17%. Note that human clinical evidence is limited. It’s extended half-life is suitable for weekly dosing. Amylin co-released with insulin from beta cells suppresses glucagon, slows gastric emptying, and increases satiety.

The drug class long-acting amylin analog works by acting at the amylin receptors (calcitonin receptor + RAMP).

How Cagrilintide Works in the Body
Cagrilintide is an engineered amylin analog with extended half-life suitable for weekly dosing. Amylin co-released with insulin from beta cells suppresses glucagon, slows gastric emptying, and increases satiety. The receptor target — amylin receptors (calcitonin receptor + RAMP) — drives the downstream effects users care about: monotherapy phase 2 showed weight loss of 6-10%; combination with semaglutide pushed total weight loss above 17%.

The pharmacokinetics matter for daily use. Cagrilintide has a half-life of approximately 7 days, which determines how often it is dosed. The standard route of administration is subcutaneous injection, and the typical schedule is once weekly. Benefits
Appetite Control
Exceptional appetite suppression through dual amylin and calcitonin receptor activation, creating powerful and sustained satiety signals

Weight Loss
Impressive 10-15% weight loss alone, or 20%+ when combined with semaglutide in the CagriSema combination

GLP-1 Synergy
Uniquely designed to complement GLP-1 medications through an independent mechanism, dramatically enhancing results when combined

Best for:

Weight loss and appetite control
Cagrilintide excels at reducing hunger by mimicking amylin, a hormone your pancreas naturally releases after meals. Phase 2 trials showed people losing up to 10.8% of body weight with cagrilintide alone – and that’s without combining it with other medications.

Boosting GLP-1 medication results
When you hit a plateau with semaglutide or want even better results, cagrilintide adds a second satiety pathway. The CagriSema combination achieved over 20% weight loss in clinical trials – significantly more than either drug alone.

People who want once-weekly convenience
Unlike older amylin medications that required three daily injections, cagrilintide’s extended half-life of about a week means you only inject once weekly. Set a reminder on your phone and you’re done.

Those seeking natural-feeling appetite reduction
Cagrilintide works by enhancing your body’s own fullness signals rather than forcing you to eat less. Many users report feeling genuinely satisfied with smaller meals rather than fighting willpower battles.

Metabolic health improvement
Beyond weight loss, cagrilintide helps with blood sugar control and metabolic markers. It slows stomach emptying and reduces post-meal glucose spikes, making it valuable for people with or at risk for type 2 diabetes.